• Biomolecules & Therapeutics
• /
• 제8권4호
• /
• pp.318-324
• /
• 2000

We have examined inhibitory erects on gasritis using omeprazole-cholestyramine resinate, which has been developed to increase the stability of omeprazole, the well-known proton pump inhibitor, in an acidic condition. To test the pharmacological action of this, we investigated the effect of omeprazole-cholestyramine resinate on indomethacin-induced gastritis in rats. Omeprazole was used as a reference drug. Orally administered omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate on the gastritis was similar to that of reference drug. In addition, rectal adminstration of the omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate was equipotent to reference drug. The basal gastric acid secretion was decreased when it was administered either orally or rectally. This inhibition of omfprazole-cholestyramine resinate was similar to that of omeprazole. These data suggest that omeprazole-cholestyramine resinate inhibit the gastritis in rats, and are comparable to omeprazole available in market.

• The Korean Journal of Physiology and Pharmacology
• /
• 제16권6호
• /
• pp.399-404
• /
• 2012

We investigated inhibitory effects of extract containing quercetin-3-O-${\beta}$-D-glucuronopyranoside (ECQ) extracted from Rumex Aquaticus Herba on indomethacin-induced gastric damage in Rats. Gastritis was induced in male Sprague-Dawley rats (200~220 g) by oral administration of indomethacin at a dose of 40 mg/kg. One hour before administration of indomethacin, animals were orally pretreated with ECQ at doses of 0.3, 1, 3 or 10 mg/kg. Six hours after indomethacin administration, the rats were sacrificed and the stomach was excised and opened along the greater curvature, and the surface area of gastric lesion was measured using optical microscope. Superoxide dismutase (SOD), catalase (CAT), myeloperoxidase (MPO) activities and malondialdehyde (MDA) levels were measured by ELISA. Western blot analysis was performed to detect protein expression of SOD-2. Linear hemorrhagic mucosal lesions were observed in the stomach 6 hours after oral administration of indomethacin. Pretreatment with ECQ significantly reduced the severity of the lesions in a dose-dependent manner. It also inhibited the reductions in SOD and CAT activities and SOD expression by the indomethacin-induced gastric damage. In addition, the pretreatment with ECQ significantly suppressed the elevation of the MPO activity and the MDA levels induced by indomethacin. These results suggest that ECQ has the inhibitory effects via antioxidative action against indomethacin-induced gastritis in rats.

• 한국식품저장유통학회지
• /
• 제24권7호
• /
• pp.1017-1024
• /
• 2017

본 연구에서는 까마귀쪽나무열매추출물(LJF-HE)의 흰쥐모델에서 인도메타신으로 유발되어지는 위염에 대한 억제효과를 확인하고자 하였다. 까마귀쪽나무열매추출물 투여그룹(LJF-HE-L, LJF-HE-M, LJF-HE-H)에서 염증길이와 위액량이 control 그룹에 비하여 통계적으로 유의하게 감소한 결과를 얻었다. 또한 위액량의 유의적인 감소효과로 위산분비가 억제되어 공격인자 작용이 약해지는 원인과 펩신의 활성도를 낮추는 원인으로 인하여 위염발생을 억제하는 것으로 판단되어진다. 까마귀쪽나무열매추출물(LJF-HE)의 위산 분비 억제 기능은 gastrin 및 histamine에 의해 발현되는 CCK-2r와 H2r 유전자의 발현을 억제하여, gastrin 및 histamine에 의한 위산 생성 단계를 조절하여, proton pump인 H+/K+ ATPase 유전자 발현을 억제시키며, 그 결과로 인하여 위산 분비를 억제하는 것으로 판단되어진다. 그리고 까마귀쪽나무열매추출물은 점액을 증가시켜 위 점막을 보호하는 PGE2의 함량을 높여, 위 점막 보호 기능을 나타내고 있으며, 더불어 염증성 cytokine인 TNF-${\alpha}$와 IL-$1{\beta}$의 생성을 낮춰주어 염증 매개반응을 저해하는 것으로 판단되어진다. 이와 같은 결과를 종합하면 까마귀쪽나무열매추출물(LJF-HE)이 인도메타신으로 유발되어지는 위염에 대한 억제효과가 있는 것으로 판단되었다.

• Biomolecules & Therapeutics
• /
• 제17권1호
• /
• pp.57-61
• /
• 2009

This study examined whether or not a pretreatment with dehydroepiandrosterone (DHEA) has an effect on indomethacin-induced gastric mucosal damage. The DHEA group, male Sprague-Dawley rats, was administrated with DHEA orally at a dose of 4 mg/day for one week before inducing gastritis with indomethacin (50 mg/kg, p.o.). Histological assay, lipid peroxidation assay, superoxide dismutase (SOD), glutathione peroxidase (GPx) and Catalase activities were determined. Interestingly, it was found that the DHEA pretreatment attenuated the gastric lesion area induced by indomethacin. Rather, the pretreatment with high dose of DHEA led to submucosal edema, leukocyte infiltration in submucosa and mucosal necrosis. The levels of MDA in the DHEA pretreatment were also higher than those in the rats given with vehicle pretreatment. This suggests that the DHEA pretreatment deteriorates severe inflammation in indomethacin-induced gastritis. DHEA supplementation significantly increased SOD activity in the gastric mucosa. However, the catalase and GPx activities were not altered by DHEA. The co-administration of DHEA with an indomethacin might not offer a protective effect against the acute gastritis induced by indomethacin.

• The Korean Journal of Physiology and Pharmacology
• /
• 제13권4호
• /
• pp.295-300
• /
• 2009

It was evaluated the inhibitory action of quercetin-3-O-${\beta}$-D-glucuronopyranoside (QGC) on reflux esophagitis and gastritis in rats. QGC was isolated from the herba of Rumex Aquaticus. Reflux esophagitis or gastritis was induced surgically or by administering indomethacin, respectively. Oral QGC decreased ulcer index, injury area, gastric volume, and acid output and increased gastric pH as compared with quercetin. Furthermore, QGC significantly decreased gastric lesion sizes induced by exposing the gastric mucosa to indomethacin. Malondialdehyde levels were found to increase significantly after inducing reflux esophagitis, and were reduced by QGC, but not by quercetin or omeprazole. These results show that QGC can inhibit reflux esophagitis and gastritis in rats.

• Journal of Microbiology and Biotechnology
• /
• 제14권5호
• /
• pp.996-1003
• /
• 2004

Nonsteroidal anti-inflammatory drugs such as indomethacin induce severe gastric mucosal damage in humans and rodents. In the present study, the in vivo protective effect of astaxanthin on indomethacin-induced gastric lesions in rats was investigated. The test groups were injected with indomethacin (25 mg/kg) after the oral administration of astaxanthin (25 mg/kg) for 1, 2, and 3 days, while the control group was treated only with indomethacin. Thiobarbituric acid reactive substances in the gastric mucosa, as an index of lipid peroxidation, increased significantly after indomethacin administration and this increase was inhibited by oral administration of astaxanthin. In addition, pretreatment with astaxanthin resulted in a significant increase of the activities of superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-px). Histologic examination clearly revealed acute gastric mucosal lesions induced by indomethacin in the stomach of the control group, but were not observed in that of the test group. These results indicate that astaxanthin activates SOD, catalase, and GSH-px, and removes the lipid peroxides and free radicals induced by indomethacin. It is evident that astaxanthin acts as a free radical quencher and antioxidant, and is an effective molecule in the remedy of gastric mucosal lesions.

• Biomolecules & Therapeutics
• /
• 제20권2호
• /
• pp.239-244
• /
• 2012

This study examined the inhibitory effects of 4-guanidinobutyric acid (4GBA), an alkaloid, against gastric lesions by assessing the inhibition of Helicobacter pylori (H. pylori) and gastric cancer cells. Acute and chronic gastritis were also observed using HCl/ethanol (EtOH) and indomethacin-induced gastric lesion models, respectively. 4GBA inhibited the growth of H. pylori in a dose dependent manner, and showed acid-neutralizing capacity. In the pylorus ligated rats, 4GBA decreased the volume of gastric secretion and gastric acid output slightly, and increased the pH. 4GBA at a dose of 100 mg/kg reduced the size of HCl/EtOH-induced gastric lesions (70.8%) and indomethacin-induced gastric lesions (38.8%). The antigastritic action of 4GBA might be associated with the acid-neutralizing capacity, anti-H. pylori action, and decreased volume of gastric secretion. These results suggest that 4GBA might be useful in the treatment and/or protection of gastritis.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.265.2-265.2
• /
• 2002

It is well known that flavonoids are the inhibitory effects on inflammations. This study was designed to determine the anti-inflammatory effects of luteolin-7-O-${\beta}$D-glucuronopyranoside (LGC). newly synthesized flavonoids. which was extracted from Salix gilgiana leaves. We investigated the protective action of LGC on reflux esophagitis and gastritis in rats. Esophagitis and gastritis were induced by surgical procedures and the exposure to indomethacin (50 mg/kg), respectively. LGC was injected intraduodenally immediately after the surgical procedures and the exposure to indomethacin (omitted)

• 한국식품위생안전성학회지
• /
• 제7권2호
• /
• pp.83-89
• /
• 1992

정향의 mathanol 추출물로 HCI-ethanol 위손상 실험을 하여 그 방어 효과를 확인하고 이를 계통 분획한 후 각 분획에 대한 HCI-ethanol 위손상실험, 기초위액 분비실험, indomethancin 위손상실험, acetic acid 궤양 실험을 하여 추출물에 대한 급성독성과 급.만성위염 및 위손상에 대한 실험한 바 다음과 같은 결과를 얻었다. (1) $LD_{50}$은 경구투여시 3000 mg/Kg 이사이었다. (2)HCL.ethanol 위손상실험에서 EtOAc fr. 165mg/Kg과 BuOH fr. 215mg/Kg에서 손상의 크기를 유의성있게 감소시켰다. (3) Acetic Acid 궤양 실험에서 위궤양의크기가 BuOH 분획 215mg/Kg으로 유의성 있게 감소되었다. 이상의 결과로서 생각은 급만성 위염 및 위손상에 대한 세포보호 작용이 있으며 그 작용기전은 위액분비의 억제작용에 인한 것이며 그 유효성분은 대부분 butanol 분획에 존재하는 것으로 생각된다.

• Archives of Pharmacal Research
• /
• 제29권6호
• /
• pp.484-489
• /
• 2006

This Study evaluated the inhibitory action of $luteolin-7-O-{\beta}-D-glucuronopyranoside$, luteolin which was isolated from Salix gilgiana leaves, and omeprazole on reflux esophagitis and gastritis in rats. Reflux esophagitis and gastritis were induced surgically and by the administration of indomethacin, respectively. The intraduodenal administration of $luteolin-7-O-{\beta}-D-glucuronopyranoside$ decreased the ulcer index, injury area, gastric volume and acid output, and increased the gastric pH compared with luteolin. $Luteolin-7-O-{\beta}-D-glucuronopyranoside$ significantly decreased the size of the gastric lesions that had been induced by exposing the gastric mucosa to indomethacin. The malondialdehyde content, which is the end product of lipid peroxidation, was increased significantly after inducing of reflux esophagitis. The malondialdehyde content was decreased by $Luteolin-7-O-{\beta}-D-glucuronopyranoside$ but not luteolin or omeprazole. $Luteolin-7-O-{\beta}-D-glucuronopyranoside$ has a more potent antioxidative effect than luteolin. $Luteolin-7-O-{\beta}-D-glucuronopyranoside$ is a promising drug for the treatment of reflux esophagitis and gastritis.